Results 101 to 110 of about 57,323 (255)

Direct tumour–adipocyte contact / Stroma AReactive Invasion Front Area (TAC/SARIFA) predicts adverse outcome in colorectal cancer: a focused evidence synthesis and meta‐analysis

Histopathology, EarlyView.
TAC/SARIFA, defined by direct tumour–adipocyte contact at the invasion front, represents a reproducible, biologically meaningful H&E biomarker with consistent adverse prognostic associations in CRC. Aims Direct tumour‐adipocyte interaction at the invasion front, termed Stroma AReactive Invasion Front Areas (SARIFA), has recently emerged as a novel H&E ...
Nic G Reitsam, Bruno Märkl, Iris D Nagtegaal, Magali Svrcek   +3 more
wiley   +1 more source

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer

Cancer Treatment and Research Communications
Purpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment
Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff   +13 more
doaj   +1 more source

UGT1A1 polymorphisms in cancer: impact on irinotecan treatment

, 2017
Masashi Takano1 Toru Sugiyama2 1Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, 2Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Iwate, Japan Abstract: Mutations in the UGT1A1 ...
Takano M, Sugiyama T
core  

Transpapillary Placement of a Multihole Covered Metal Stent Using a 5.9‐Fr Delivery System Through a Forward‐viewing Endoscope in Malignant Biliary Obstruction With Type I Duodenal Stenosis

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Concurrent malignant biliary obstruction (MBO) and type I duodenal stenosis represent a technically demanding scenario, as luminal narrowing frequently precludes passage of a standard side‐viewing duodenoscope and limits conventional transpapillary drainage.
Kengo Matsumoto, Daisuke Kondo, Satoru Okabe, Naoto Osugi, Akira Doi, Masashi Yamamoto, Shiro Hayashi, Koji Fukui, Tsutomu Nishida   +8 more
wiley   +1 more source

Irinotecan or FOLFIRI for 2nd line colorectal [PDF]

, 2011
Background Second-line treatment with irinotecan for advanced or metastatic colorectal cancer prolongs survival. It is uncertain whether irinotecan is better administered with 5- fluorouracil or alone in patients previously treated with a ...
Ransom, David T, Gebski, Val, Yip, Sonia, Tebbutt, Niall C, Buck, Martin, Simes, R John, Boland, Amy, Clarke, Stephen, Zalcberg, John, Brown, Chris, Van Hazel, Guy, Lowenthal, Raymond M, Jeffrey, G Mark, Goldstein, David   +13 more
core  

Rifaximin alleviates irinotecan-induced diarrhea in mice model

Annals of Medicine
Background Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Chengyi Huang, Huiyin Lan, Minghua Bai, Jinggang Chen, Shengkun Xu, Quanquan Sun, Qianping Chen, Wei Mao, Jin Jiang, Ji Zhu   +9 more
doaj   +1 more source

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview

, 2001
PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic
Wolf Achterrath, Udo Vanhoefer, Andreas Harstrick, Siegfried Seeber, Shousong Cao, Youcef M. Rustum   +5 more
core   +1 more source

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study

International Journal of Cancer, Volume 159, Issue 8, Page 2075-2083, 15 October 2026.
Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut   +9 more
wiley   +1 more source

Voltammetric Characterisation of Anticancer Drug Irinotecan

, 2017
Electrochemical reduction of irinotecan was investigated on a static mercury drop electrode using square-wave voltammetry. The mechanism of irinotecan electroreduction is a complex, pH-dependent, quasireversible process and includes the transfer of two ...
Jovanović-Novak, Ivana, Marijana Neuberg, Komorsky-Lovrić, Šebojka, Ana Lucić Vrdoljak, Ivana Novak Jovanović, Lucić-Vrdoljak, Ana, Šebojka Komorsky-Lovrić, Neuberg, Marijana, Aleksandar R. Popović, Popović, Aleksandar R.   +9 more
core   +1 more source

A Roadmap to Individualized Irinotecan Dosing [PDF]

, 2006
Ever since its introduction to the drug-market in the late eighties, early nineties of the last century, irinotecan is fighting its image. Particularly, the unpredictable occurrence and severity of delayed-type diarrhea, its main dose-limiting ...
de Jong, FA (Floris), Jong, F.A. (Floris) de   +1 more
core   +1 more source